سعر اديروبان 8 مجم 20 قرص 2025

Eduropan 8 mg film-coated tablets (lornoxicam 8 mg), 20 tablets; Al Rowad / Hygint, Egypt.

• Short-term relief of acute mild to moderate pain; symptomatic relief of pain and inflammation in osteoarthritis and rheumatoid arthritis.Population: AdultsHPRA / Takeda — Xefo 8 mg SmPC

• Common: nausea, abdominal pain, dyspepsia, diarrhoea, vomiting, mild headache, dizziness. GI ulcers/bleeding and oedema/hypertension/cardiac failure reported with NSAID class.International label, same formulation · HPRA / Takeda — Xefo 8 mg SmPC

• Hypersensitivity to lornoxicam or NSAIDs (including aspirin); thrombocytopenia; severe heart failure; GI bleeding/ulcer per SmPC criteria; severe hepatic impairment; severe renal impairment (serum creatinine >700 µmol/L); third trimester of pregnancy.International label, same formulation · HPRA / Takeda — Xefo 8 mg SmPC

• GI bleeding, ulceration or perforation risk (higher in elderly/history of ulcer); possible small increase in arterial thrombotic events with NSAIDs; monitor renal function in at-risk patients; discontinue at first sign of serious skin reaction; avoid concomitant NSAIDs.International label, same formulation · HPRA / Takeda — Xefo 8 mg SmPC

• Anticoagulants (e.g. warfarin)MajorNSAIDs may enhance anticoagulant effects; monitor INR.HPRA / Takeda — Xefo 8 mg SmPC
• Other NSAIDs / corticosteroids / SSRIs / antiplatelet agentsMajorIncreased risk of gastrointestinal ulceration or bleeding.HPRA / Takeda — Xefo 8 mg SmPC

• Contraindicated in the third trimester. Not recommended in first/second trimester (limited human data; prostaglandin synthesis inhibition risks). Should not be used in breastfeeding women (excreted in animal milk; no human data).International label, same formulation · HPRA / Takeda — Xefo 8 mg SmPC

• Lornoxicam: Inhibits COX-1 and COX-2, reducing prostaglandin/thromboxane synthesis → analgesic, anti-inflammatory, antipyretic effects.